CSF3 and cyclic hematopoiesis: However, we noted that in the CRC cohort, no patients with CH-PD received triplet chemotherapy, likely related to their older age at diagnosis, compared with patients without CH-PD, of whom 15 (7.3%) received triplet chemotherapy, which may explain why patients without CH-PD appeared to require more G-CSF support.